Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis

Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis

Background In cirrhosis, a decrease in hepatic venous pressure gradient (HVPG) > 10% after acute iv propranolol (HVPG response) is associated with a lower risk of decompensation and death. Only a part of patients are HVPG responders and there are no accurate non‐invasive markers to identify them....

Full description

Saved in:
Bibliographic Details
Published in:Liver international Vol. 39; no. 4; pp. 705 - 713
Main Authors: Reverter, Enric, Lozano, Juan J., Alonso, Cristina, Berzigotti, Annalisa, Seijo, Susana, Turon, Fanny, Baiges, Anna, Martínez‐Chantar, Mari L., Mato, José M., Martínez‐Arranz, Ibon, La Mura, Vincenzo, Hernández‐Gea, Virginia, Bosch, Jaume, García‐Pagán, Juan C.
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01-04-2019
Subjects:
Adrenergic beta-Antagonists - administration & dosage
Aged
Biomarkers
Biomarkers - blood
Cirrhosis
Classification
Fatty acids
Female
Humans
Hypertension, Portal - blood
Hypertension, Portal - complications
Hypertension, Portal - drug therapy
Infusions, Intravenous
Lecithin
Liquid chromatography
Liver cirrhosis
Liver Cirrhosis - blood
Liver Cirrhosis - complications
Liver Cirrhosis - drug therapy
Logistic Models
Male
Mass spectrometry
Mass spectroscopy
Mercury
metabolite
Metabolites
Metabolomics
Middle Aged
Multivariate Analysis
non‐selective beta‐blockers
Patients
Phosphatidylcholine
portal hypertension
Predictive Value of Tests
Propranolol
Propranolol - administration & dosage
Regression analysis
variceal bleeding
Venous Pressure - drug effects
non-selective beta-blockers
metabolite
portal hypertension
variceal bleeding
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In cirrhosis, a decrease in hepatic venous pressure gradient (HVPG) > 10% after acute iv propranolol (HVPG response) is associated with a lower risk of decompensation and death. Only a part of patients are HVPG responders and there are no accurate non‐invasive markers to identify them. We aimed at discovering metabolomic biomarkers of HVPG responders to propranolol. Methods Sixty‐six patients with cirrhosis and HVPG ≥ 10 mm Hg in whom the acute HVPG response to propranolol was assessed, were prospectively included. A targeted metabolomic serum analysis using ultrahigh‐performance liquid chromatography coupled to mass spectrometry was performed. Different combinations of 2‐3 metabolites identifying HVPG responders (HVPG reduction > 10%) were obtained by stepwise logistic regression. The best of these model (AUROC, Akaike criterion) underwent internal cross‐validation and cut‐offs to classify responders/non‐responders was proposed. Results A total of 41/66 (62%) patients were HVPG responders. Three hundred and eighty‐nine metabolites were detected and 177 were finally eligible. Eighteen metabolites were associated to the HVPG response at univariate analysis; at multivariable analysis, a model including a phosphatidylcholine (PC(P‐16:0/22:6)) and a free fatty acid (20:2(n‐6), eicosadienoic acid) performed well for HVPG response, with an AUROC of 0.801 (0.761 at internal validation). The cut‐off 0.629 was the most efficient for overall classification (49/66 patients correctly classified). Two cut‐off values allowed identifying responders (0.688, PPV 84%) and non‐responders (0.384, NPV 82%) with undetermined values for 17/66 patients. Clinical variables did not add to the model. Conclusions The combination of two metabolites helps at identifying HVPG responders to acute propranolol. It could be a useful non‐invasive test to classify the HVPG response to propranolol.
Bibliography:Funding information
This study was supported by the Ministry of Education and Science (SAF‐2016‐75767‐R), and Instituto de Salud Carlos III (PI13/00341, FEDER "Una manera de hacer Europa"). CIBERehd (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) is funded by the ISC III. ER was recipient of a Río Hortega award (2012‐13), ISC III.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14042